

10. Arias TD, Jorge LF, Inaba T. No evidence for the present of poor metabolizers of sparteine in an Amerindian group. Br J Clin Pharmacol, 21, 547-549, 1986.
11. Arunkumar Shastri R. Undernourished adults and acetylation phenotype. Int J Clin Pharmacol Ther Toxicol, 20, 194-196, 1982.
12. Arvela P, Kirjarinta M, Krki N, Pelkonen O. Polymorphism of debrisoquine hydroxylation among Finns and Lapps. Br J Clin Pharmacol, 26, 601-603, 1988.
13. Azad Khan AK, Nurazzaman M, Truelove SC. The effect of the acetylator phenotype on the metabolism of suphasalazine in man. J Med Genetics, 20, 30-36, 1983.
14. Balant-Gorgia AE, Schulz P, Dayer P, Balant L, Kubli A, Gertsch C, Garrone G. Role of oxidation polymorphism on blood and urine concentrations of

amitriptyline and its metabolites in man. Arch Psychiat Neurol Sci, 232, 215-222, 1982.

15. Bamrah JS, Soni SD. Drug-induced Parkinson's disease. Lancet, 1, 1031-1032, 1987.
16. Barbeau A, Cloutier T, Roy M, Plasse L, Paris S, Poirier J. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet, 2, 1213-1216, 1985.
17. Barclay WR, Ebert RH, Le Roy GV, Manthei RW, Roth LJ. Distribution and excretion of radioactive isoniazid in tuberculous patients. JAMA, 151, 1384-1388, 1953.
18. Batchelor JR, Welsh KI, Mansilla-Tinoco R, Collery CT, Hughes GRV, Bernstein R, Ryan P, Naish PF, Abler GM, Bing RF, Russell GI. Hydralazine-induced systemic lupus erythematosus: Influence of HLA-DR and sex on susceptibility.. Lancet, 1, 1107-1109, 1980.

19. Benítez J, Llerena A, Cobaleda J. Debrisoquin oxidation polymorphism in a Spanish population. Clin Pharmacol Ther, 44, 74-77, 1988.
20. Bertilsson L, Aberg-Wistedt A. The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. Br J Clin Pharmacol, 15, 388-390, 1983.
21. Bertilsson L, Dengler HJ, Eichelbaum M, Schultz HU. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine. Eur J Clin Pharmacol, 17, 153-155, 1980.
22. Bertilsson L, Eichelbaum M, Mellstrom B, Sawe J, Schultz HU, Sjqvist F. Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci, 27, 1673-1677, 1980.
23. Bienzle U. Glucose-6-phosphate dehydrogenase deficiency. Part I: Tropical Africa. Clin Haematol, 10, 785-799, 1981.

24. Blain PG, Mucklow JC, Wood P, Roberts DF, Rawlins MD. Family study of antipyrine clearance. Br Med J, 284, 150-152, 1982.
25. Bloom, GE, Zarkowsky HS. Heterogeneity of the enzymatic defect in congenital methemoglobinemia. N Engl J Med, 281, 919, 1969.
26. Bodansky HJ, Drury PL, Cudworth AG, Price Evans DA. Acetylator phenotypes and type I (insulin-dependent) diabetics with microvascular disease. Diabetes, 30, 907-910, 1981.
27. Boobis AR, Murray S, Khan GC, Robertz G-M, Davies DS. Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man. Mol Pharmacol, 23, 471-481, 1983.
28. Breimer DD. Interindividual variations in drug disposition: clinical implications and methods of investigation. Clin Pharmacokin, 8, 371-377, 1983.

29. Brosen K, Otton SV, Gram LF. Spartein oxidation polymorphism in Denmark. Acta Pharmacol Toxicol, 57, 357-360, 1985.
30. Brosen K, Gram LF. Clinical significance of the sparteine/debrisoquine oxydation polymorphism. Eur J Clin Pharmacol, 36, 537-547, 1989.
31. Bulovskaya LN, Krupkin RG, Bochina TA, Shipkova AA, Pavlova MV. Acetylator phenotype in patients with breast cancer. Oncology, 35, 185-188, 1978.
32. Burns RS, Markey SP, Philips JM, Chilich CC. The neurotoxicity of 1-methyl-4-phenyl-1-1,2,3,6-tetrahydropyridine in the monkey and man. Can J Neurol Sci, 11 (suppl), 166-169, 1984.
33. Burrows AW, Hockaday TDR, Mann JI, Taylor JG. Diabetic dimorphism according to acetylator status. Br Med J, 1, 208-210, 1978.

34. Calne DB, Eisen A, McGeer E, Spencer P. Alzheimer's disease, Parkinson's disease, and motoneurone disease: abiotropic interaction between ageing and environment?. Lancet, 2, 1067-1070, 1986.
35. Calne DB, Langston JW. Aetiology of Parkinson's disease. Lancet, 2, 1457-1459, 1983.
36. Cartwright RA, Glashen RW, Rogers HJ, Ahmad RA, Barham-Hall D, Higgins E, Kahn MA. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet, 2, 842-845, 1982.
37. Chapman CJ. Drugs and genes: therapeutic implications. Drugs, 14, 120-127, 1977.
38. Champman LJ, Peters HA, Matthews CG, Levine RL. Parkinsonism and industrial chemicals. Lancet, 1, 332-333, 1987.

39. Chapron DJ, Blum MR. Relationship of sulphamethazine disposition kinetics to acetylator phenotype in man. J Clin Pharmacol, 16, 338-344, 1976.
40. Chapron DJ, Kramer PA, Mercik SA. Potential influence of body weight on the clearance of polymorphically acetylated drugs. J Clin Pharmacol, 22, 271-275, 1982.
41. Clark DWJ. Simultaneous phenotyping for oxidation and acetylation status. Proceedings of the University of Otago Medical School Dunedin NZ, 61, 30-32, 1983.
42. Clark DWJ, Blain PG, Rawlins MD, Roberts DH. Pharmacogenetic screening in the general population. (Abstract). Clin Exp Pharmacol Physiol, Suppl 8, 67, 1984.
43. Clark DWJ, Morgan A, Waal-Manning H. Adverse effects from metoprolol are not generally associated with oxidation status. Br J Clin Pharmacol, 18, 965-967, 1985.

44. Clark DWJ. Genetically determined variability in acetylation and oxidation. Therapeutic implications. Drugs, 29, 342-375, 1985.
45. Clark DWJ, Edwards IR. Adverse drug reaction reporting and retrospective phenotyping for oxidation polymorphism. Med Toxicol, 3, 241-247, 1988.
46. Cohen RJ, Sachs JR, Wicker DJ, Conrad ME. Methemoglobinemia provoked by malarial chemoprophylaxis in Vietnam. N Engl J Med, 279, 1127-1131, 1968.
47. Coombes RC, Foster AB, Harland SJ, Jarman M, Nice EC. Polymorphically acetylated aminoglutethimide in humans. Br J Cancer, 46, 340-345, 1982.
48. Cooper RG, Price Evans DA, Whibley EJ. Polymorphic hydroxylation of perhexiline maleate in man. J Med Genetics, 21, 27-33, 1984.

49. Cowan GO, Das KM, Eastwood MA. Further studies of sulphasalazine metabolism in the treatment of ulcerative colitis. Br Med J, 2, 1057-1059, 1977.
50. Danhof M, de Groot-van der Vis E, Breimer DD. Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography with some preliminary results in man. Pharmacology, 18, 210-223, 1979.
51. Danhof M, Idle JR, Teunissen NWE, Sloan TP, Breimer DD, Smith RL. Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation. Pharmacology, 22, 349-358, 1981.
52. Davidson J, McLeod NN, Blum MR. Acetylation phenotype, platelet monoamine oxydase inhibition, and the effectiveness of phenelzine in depression. Am J Psychiat, 135, 467-469, 1978.

53. Davies DS, Beedie MA, Rawlins MD. Antinuclear antibodies during procainamide treatment and drug acetylation. Br Med J, 3, 682-683, 1975.
54. Davies DS, Boobis AR. Variants of human microsomal enzymes. Biochem Soc Transactions, II, 459-460, 1983.
55. Davis GC, Williams AC, Markey SP, et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiat Res, 1, 249-254, 1979.
56. Dayer P, Balant L, Kupfer A, Courvoisier F, Fabre J. Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents. Eur J Clin Pharmacol, 24, 797-799, 1983.
57. Dayer P, Courvoisier F, Balant L, Fabre J. Beta-blockers and drug oxidation status. Lancet, 1, 509, 1982.

58. Dayer P, Leemannt T, Marmy A, Rosenthaler J.
Interindividual variation of beta-adrenoreceptor
blocking drugs, plasma concentration and effect:
influence of genetic status on behaviour of atenolol,
bopindol and metoprolol. Eur J Clin Pharmacol, 28,
149-153, 1985.
59. De Luca HF, Suttie JW (eds). The Fat soluble vitamins.
University of Wisconsin Press. Madison, 1970.
60. De Matteis F. Disturbances of liver porphyrin
metabolism caused by drugs. Pharmacol Rev, 19,
523-557, 1967.
61. de Wolff FA, Vermeij P, Ferrari MD, Buruma OJS,
Breimer DD. Impairment of phenytoin parahydroxylation
as a cause of severe intoxication. Ther Drug Monit,
5, 213-215, 1983.
62. Devadatta S, Gangadharan PRJ, Andrews RH, Fox W,
Ramakrishnan CV, Shelon JB, Veru S. Peripheral
neuritis due to isoniazid. Bull World Health

Organization, 23, 587-598, 1960.

63. Dickinson DS, Bailey WC, Hirschowitz DI, Soong SJ, Eidus L, Hodking MM. Risk factors for isoniazid (INH)-induced liver dysfunction. J Clin Gastroenterol, 3, 271-279, 1981.
64. Drayer DE, Reidenberg MM. Clinical consequences of polymorphic acetylation of basic drugs. Clin Pharmacol Ther, 22, 251-258, 1977.
65. Drayer DE, Reidenberg MM, Sevy RW. N-acetylprocainamide: an active metabolite of procainamide. Proc Soc Exp Biol Med, 146, 358-363, 1974.
66. Drayer P, Leeman T, Striberni R. Dextrometorphan O-demethylation in liver microsomes as a prototype to monitor cytochrome P450 db1 activity. Clin Pharmacol Ther, 45, 34-40, 1989.
67. du Souich P, Lalka D, Slaughter R, Elvin AT, McLean

AJ. Mechanisms of non-linear disposition kinetics of sulphamethazine. Clin Pharmacol Ther, 25, 172-183, 1979.

68. du Souich P, McLean AJ, Stoeckel K, Ohlendorf D, Gibaldi M. Screening methods using sulphamethazine for determining acetylator phenotype. Clin Pharmacol Ther, 26, 757-765, 1979.
69. Ehrenfeld N, Zylber-Katz E, Levy M. Acetylator phenotype in rheumatoid arthritis. Israel J Med Sci, 19, 368-379, 1983.
70. Eichelbaum M. Defective oxidation of drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokin, 7, 1-22, 1982.
71. Eichelbaum M, Bertilsson L, Sawe J. Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine. Br J Clin Pharmacol, 15, 317-321, 1983.

72. Eichelbaum M, Bertilsson L, Sawe J, Zekorn C.
Polymorphic oxidation of sparteine and debrisoquine:
related pharmacogenetic entities. Clin Pharmacol
Ther, 31, 184-186, 1982.
73. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ.
Defective N-oxidation of sparteine in man: a new
pharmacogenetic defect. Eur J Clin Pharmacol, 16,
183-187, 1979.
74. Eichelbaum M, Woolhouse NM. Inter-ethnic differences in
sparteine oxydation among Ghanaians and Germans. Eur
Clin Pharmacol, 28, 79-83, 1985.
75. Eidus L, Harnanansingh HM, Jessamine AG. Urine test
for phenotyping isoniazid inactivators. Am Rev Respir
Dis, 104, 587, 1971.
76. Eidus L, Ling GM, Harnanansingh AMT. Isoniazid
excretion in fast and slow inactivators and its
practical aspect for phenotyping. Arzneimittel-
Forschung, 21, 1696-1699, 1971.

77. Ellard GA. Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pylmonary tuberculosis. Clin Pharmacol Ther, 19, 610-625, 1976.
78. Ellard GA, Gammon PT. Acetylator phenotyping of tuberculosis patients using matrix isoniazid or sulphadimidine and its prognostic significance for treatment. Br J Clin Pharmacol, 4, 5-14, 1977.
79. Elson J, Strong JM, Atkinson Jr AJ. Antiarrythmic potency of N-acetylprocainamide. Clin Pharmacol Ther, 17, 134-140, 1975.
80. Erdtmansky P, Goelh TJ. Gas-liquid chromatographic electron capture determination of some monosubstituted guanido-containing drugs. Analytical Chemistry, 47, 750-752, 1975.
81. Farah F, Taylor W, Rawlins MD, James O. Hepatic drug acetylation and oxidation: effects of ageing in man. Br Med J, 2, 155-156, 1977.

82. Fine A, Summer DJ. Determination of acetylator status in uraemia. Br J Clin Pharmacol, 2, 475-476, 1975.
83. Fishbein E, Alarcon-Segovia D. Slow acetylation phenotype in systemic lupus erythematosus. Arthr Rheumat, 22, 95-96, 1979.
84. Foad B, Litwin A, Zimmer H, Hess EV. Acetylator phenotype in systemic lupus erythematosus. Arthr Rheumat, 20, 815-818, 1977.
85. Gachályi B, Vas Á, Hajós P, Káldor A. Acetylator phenotypes: effect of age. Eur J Clin Pharmacol, 26, 43-45, 1984.
86. Gelber R, Peters JH, Gordon GR, Glazko AJ, Levy L. The polymorphic acetylation of dapsone in man. Clin Pharmacol Ther, 12, 225-238, 1971.
87. Girling DJ. The hepatic toxicity of antitubercular regimes containing isoniazid, rifampicin and pyrazinamide. Tubercle, 59, 13-32, 1978.

88. Glowinski IB, Radtke HE, Weber WW. Genetic variation in N-acetylation of carcinogenic arylamines by human and rabbit liver. Molec Pharmacol, 14, 940-949, 1978.
89. Goldstein PD, Alpers DH, Keating JT. Sulphapyridine metabolites in children with inflammatory bowel disease receiving sulphasalazine. J Pediatr, 95, 638-640, 1979.
90. Graham JB, Falls VV, Winters RW. Familial hypophosphatemia with vitamin D resistant rickets. II. Three additional kindreds of the sex-linked dominant type with a genetic analysis of four such families. Amer J Human Genet, 11, 311, 1959.
91. Grant DM, Tang BK, Kalow W. Polymorphic N-acetylation of a caffeine metabolite. Clin Pharmacol Ther, 33, 355-359, 1983.
92. Grant DM, Tang BK, Kalow W. Variability in caffeine

- metabolism. Clin Pharmacol Ther, 33, 591-602, 1983.
93. Grant DM, Tang BK, Kalow W. A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol, 17, 459-464, 1984.
94. Gronhagen-Riska C, Helstrom PE, Froseth B. Predisposing factors in hepatitis induced by isoniazid-rifampicin treatment of tuberculosis. Am Rev Respir Dis, 118, 461-466, 1978.
95. Hall S. Evaluation of the sulphadimidine acetylator phenotyping test in a patient with reduced renal function. Acta Med Scand, 209, 505-507, 1981.
96. Hanson A, Mclander A, Wahlin , Boll E. Acetylator phenotyping: a comparison of the isoniazid and dapsona tests. Eur J Clin Pharmacol, 20, 233-234, 1981.
97. Harland SJ, Facchini V, Timbrell JA. Hydralazine-

induced lupus erythematosus-like syndrome
in a patient of the rapid acetylator phenotype. Br
Med J, 281, 273-274, 1980.

98. Harris JW. The Red Cell. Harvard University Press.
Cambridge, 1970.

99. Harris H, Hopkinson DA, Luffman J. Enzyme diversity
in human populations. Ann N Y Acad Sci, 151, 232-242,
1968.

100. Horai Y, Ishizaki T. Pharmacogenetics and its
clinical implications: N-acetylation polymorphism.
Rational Drug Therapy, 21, 10-17, 1987.

101. Horai Y, Ishizaki T, Sasaki T, Koya G, Matsuyama K,
Iguchi S. Isoniazid disposition, comparison of
isoniazid phenotyping methods in and acetylator
distribution of Japanese patients with idiopathic
sistemic lupus erythematosus and control subjects. Br
J Clin Pharmacol, 13, 361-374, 1982.

102. Horai Y, Ishizaki T. N-acetylation polymorphism of dapsone in a Japanese population. Br J Clin Pharmacol, 25, 487-494, 1988.
103. Horai Y, Zhou H, Zhang L, Ishizaki T. N-acetylation phenotyping with dapsone in a mainland Chinese population. Br J Clin Pharmacol, 25, 81-87, 1988.
104. Horai Y, Ishizaki T. Pharmacogenetics and its clinical implications .PartII. Oxidation polynorphism. Rational Drug Ther, 22, 6-1, 1988.
105. Hunyor SN. Hydralazine and beta-blockade in refractory hypertension with characterization of the acetylator phenotype. Austr N Z J Med, 5, 530-536, 1975.
106. Hutchinson D, Wyld PJ. Sulphasalazine-induced agranulocytosis. N Z Med J, 96, 520-521, 1983.

107. Idle JR, Mahgoub A, Lancaster R, Smith RL. Hypotensive response to debrisoquine and hydroxylation phenotype. Life Sci, 22, 979-984, 1978.
108. Idle JR, Smith RL. Polimorphism of oxidation at carbon centers of drugs and their clinical significance. Drug Metab Rev, 9, 301-317, 1979.
109. Idle JR, Mahgoub A, Sloan TP, Smith RL, Mbanefo CO, Bababunmi EA. Some observations on the oxidation phenotype status of Nigerian patients presenting with cancer. Cancer Letters, 11, 311-338, 1981.
110. Idle JR, Oates NS, Shah RR, Smith RL. Is there a genetic predisposition to phenphormin-induced lactic acidosis? Br J Clin Pharmacol, 11, 418P-419P, 1981.
111. Idle JR, Oates NS, Shah RR, Smith RL. Protecting poor metabolisers: a group at risk of adverse reactions. Lancet, 1, 1388, 1983.

112. Idle JR, Ritchie JC, Smith RL. Oxidation phenotype and metiamide metabolism. Br J Pharmacol, 66, 432P, 1979.
113. Idle JR, Sloan TP, Smith RL, Wakile LA. Application of the phenotyped panel approach to the detection of polymorphism of drug oxidation in man. Br J Pharmacol, 66, 430P-431P, 1980.
114. Inaba T, Otton SV, Kalow W. Deficient metabolism of debrisoquine and sparteine. Clin Pharmacol Ther, 27, 547-549, 1980.
115. Inaba T, Otton SV, Kalow W. Debrisoquine hydroxylation capacity: problems of assessment in two populations. Clin Pharmacol Ther, 29, 218-223, 1981.
116. Inaba T, Vinks A, Otton SW, Kalow W. Comparative pharmacogenetics of sparteine and debrisoquine. Clin Pharmacol Ther, 33, 394-399, 1983.

117. Inaba T, Jurima M, Nakano M, Kalow W. Mephenytoin and sparteine pharmacogenetics in Canadian caucasians. Clin Pharmacol Ther, 36, 670-676, 1984.
118. Inaba T, Jorge LF, Arias TD. Mephenytoin hydroxylation in the Cuna amerindians of Panama. Br J Clin Pharmacol, 25, 75-79, 1988.
119. Ishizaki T, Horai Y, Koya G, Matsuyama K, Iguchi S. Acetylator phenotype and metabolic disposition of isoniazid in Japanese patients with systemic lupus erythematosus. Arthr Rheumat, 24, 1245-1254, 1981.
120. Islam SI, Idle JR, Smith RL. The polymorphic 4-hydroxylation of debrisoquine in a Saudi Arab population. Xenobiotica, 10, 819-825, 1980.
121. Jack DB, Kendall MJ. Beta-blockers and debrisoquine metaboliser status. Lancet, 1, 741, 1982.

122. Jack DB, Wilkins N, Quarterman CP. Lack of evidence for polymorphism in metoprolol metabolism. Br J Clin Pharmacol, 16, 188-190, 1983.
123. Johansson E, Mustakallio KK, Mattila MJ. Polymorphic acetylator phenotype and systemic lupus erythematosus. Acta Med Scand, 210, 193-196, 1981.
124. Johnstone EC, Marsh W. The relationship between response to phenelzine and acetylator status in depressed patients. Proc Royal Soc Med, 66, 947-949, 1973.
125. Jounela AJ, Pasanen M, Matilla MJ. Acetylator phenotype and the antihypertensive response to hydralazine. Acta Med Scand, 197, 303-306, 1975.
126. Jurima M, Inaba T, Kalow W. Sparteine oxidation by the human liver. Absence of inhibition by mephenytoin. Clin Pharmacol Ther, 35, 426-428, 1984.

127. Kahn GC, Boobis AR, Murray S, Brodie MJ, Davies DS. Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver. Br J Clin Pharmacol, 13, 637-645, 1982.
128. Kalow W. Pharmacogenetics: heredity and the response to drugs. WB Saunders. Philadelphia, 1962.
129. Kalow W. Topics in pharmacogenetics. Ann NY Acad Sci, 179, 654-659, 1971.
130. Kalow W. Ethnic differences in drug metabolism. Clin Pharmacokin, 7, 373-400, 1982.
131. Kappas A, Bradlow HL, Gillette PN, Levere RD, Gallagher TF. A defect of steroid hormone metabolism in acute intermittent porphyria. Fed Proc, 31, 1293, 1972.
132. Karim AKMB, Price Evans DA. Polymorphic acetylation of nitrazepam. J Med Genet, 13, 17-19, 1976.

133. Kellerman G, Kellerman ML, Horning MG, Stafford M.
Elimination of antipyrine and benzo(a)pyrene
metabolism in cultured human lymphocytes. Clin
Pharmacol Ther, 20, 72-80, 1976.
134. Kirkman HN. Glucose-6-phosphate dehydrogenase
variants and drug-induced hemolysis. Ann NY Acad
Sci, 151, 753, 1968.
135. Kitchin I, Tremblay J, Andre J, Dring LG, Idle JR,
Smith RL, Williams RT. Individual and interspecies
interaction in the metabolism of the hallucinogen
4-methoxyamphetamine. Xenobiotica, 9, 397-404,
1979.
136. Kleinbloesen CH, Van Brummelen P, Faber H, Danhof M,
Vermeulen NPE, Breimer DD. Variability in nifedipine
pharmacokinetics and dynamics: a new oxydation
polymorphism in man. Biochem Pharmacol, 33,
3721-3724, 1984.

137. Kroemer HK, Mikus G, Kronbach T, Meyer VA, Eichelbaum M.
In vitro characterization of the human cytochrome P450
involved in polymorphic oxidation of propafenone. Clin
Pharmacol Ther, 45, 28-33, 1989.
138. Kong I, Devonshire HW, Cooper M, Sloan TP, Idle JR,
Smith RL. The influence of oxidation phenotype on
phenacetin metabolism and haemotoxicity. Br J Clin
Pharmacol, 13, 275P-276P, 1982.
139. Kupfer A, Dick B, Preisig R. Polymorphic mephenytoin
hydroxylation in man: a new phenotype in the genetic
control of hepatic drug metabolism. Hepatology,
81, 34, 1981.
140. Kupfer A, Schmid B, Preisig R, Pfaff G.
Dextromethorphan as a safe probe for debrisoquine
hydroxylation polymorphism. Lancet, 2, 517-518,
1984.
141. Kutt H. Biochemical and genetic factors regulating

Dilantin metabolism in man. Ann NY Acad Sci,
179, 704-722, 1971.

142. Kutt H, Brennan R, Dehejia H, Verebely K.
Diphenylhydantoin intoxication. A complication of
isoniazid therapy. Am Rev Respir Dis, 101, 377-384,
1970.
143. Kutt H, Wolk M, Scherman R, McDowell F. Insufficient
co-hydroxylation as a cause of diphenylhydantoin
toxicity. Neurology, 14, 542-548, 1964.
144. Ladero JM, Arroyo A. Envejecimiento y fenotipo
acetilador hepático. Rev Iberoamer Invest Clin,
2, 21-26, 1983.
145. Ladero JM, Arrojo A, de Salamanca RE, Gomez M, Cano
F, Alfonso M. Hepatic acetylator phenotype in
diabetes mellitus. Ann Clin Res, 14, 187-189,
1982.

146. Ladero JM, Arrojo A, Gilsanz V. Acetilación hepática en la población española. Gastroenterol Hepatol, 2, 236-240, 1979.
147. Ladero JM, Fernández MJ, Jiménez LC. Influencia del sexo, la edad y la pigmentación corporal sobre el polimorfismo acetilador. An Med Intern (Madrid), 5, 241-244, 1988.
148. Ladero JM, Fernández HJ, Palmeiro R, Muñoz JJ, Jara C, Lázaro C, Pérez-Manga G. Hepatic acetylator polymorphism in breast cancer patients. Oncology, 44, 341-344, 1987.
149. Lahita R, Kluger J, Drayer DE, Koffler D, Reidenberg MM. Antibodies to nuclear antigens in patients treated with procainamide or acetylprocainamide. N Engl J Med, 301, 1382-1385, 1979.
150. Langston JW, Forno LS, Rebert CS, Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP). Brain Res, 292, 390-394, 1984.

151. Langston JW, Ballard P. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease. Can J Neurol Sci, 11 (suppl), 160-165, 1984.
152. Langston JW. Closer to Parkinson's disease: MPTP and the aging nervous system. Trends Pharmacol Sci, 81, 7-8, 1987.
153. Larsson R, Karlberg BE, Norlander B, Wirsen A. Prizidilol, an antihypertensive with precapillary vasodilator and beta-adrenoceptor blocking actions in primary hypertension. Clin Pharmacol Ther, 29, 588-593, 1981.
154. Larsson R, Karlsson E, Molin L. Spontaneous systemic lupus erythematosus and acetylator phenotype. Acta Med Scand, 201, 223-226, 1977.
155. Lawson DH, Henry DA, Lowe J, Reavey P, Rennie JA,

Solomon A. Acetylator phenotype in spontaneous SLE and rheumatoid arthritis. Ann Rheum Dis, 38, 171-173, 1979.

156. Leclercq V, Desager JP, van Nienwenhuyze Y, Harvengt C. Prevalence of drug hydroxylator phenotypes in Belgium. Eur J Clin Pharmacol, 33, 439-440, 1987.
157. Lee EJ, Lee LKH. A simple pharmacokinetic method for separating the three acetylation phenotypes: a preliminary report. Br J Clin Pharmacol, 13, 375-378, 1982.
158. Leden I, Hanson A, Melander A, Sturfelt G, Svensson B, Wahlin-Boll E. Varying distribution of acetylation phenotypes in RA patients with and without Sjögren's syndrome. Scand J Rheum, 10, 253-255, 1981.
159. Lennard MS, Freestone S, Ramsay LE, Tucker GT, Woods HF. Oxidation phenotype and beta-blockers. N Engl J Med, 308, 965, 1983.

160. Lennard MS, Silas JH, Smith AJ, Tucker GT.
Determination of debrisoquine and its 4-hydroxy
metabolite in biological fluids by gas chromatography
with flame-ionisation and nitrogen-selective detection.
J Chromat, 133, 161-166, 1977.
161. Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker
GT, Wood HF. Oxydation phenotype - a major
determinant of metoprolol metabolism and response.
N Engl J Med, 303, 1558-1560, 1982.
162. Lennard MS, Silas JH, Freestone S, Trevethick J.
Defective metabolism of metoprolol in poor
hydroxylators of debrisoquine. Br J Clin Pharmacol,
14, 301-303, 1982.
163. Lennard MS, Jackson PR, Freestone S, Tucker GT,
Ramsay LE, Woods HF. The relationship between
debrisoquine oxidation phenotype and the
pharmacokinetics and pharmacodynamics of propranolol.
Br J Clin Pharmacol, 17, 679-685, 1984.

164. Lennard MS, Tucker GT, Silas MD, Freestone S, Ramsay LE, Woods HF. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquine metabolizers. Clin Pharmacol Ther, 34, 732-737, 1983.
165. Lennard MS, Tucker GT, Woods HF. The polymorphic oxidation of β -adrenoceptor antagonists. Clinical pharmacokinetic considerations. Clin Pharmacokin, 11, 1-17, 1986.
166. Lennard MS, Tuccker GT, Woods HF, Silas JH, Iyun AO. Stereoselective metabolism of metoprolol-relationship to debrisoquine oxydation phenotype. Br J Clin Pharmacol, 27, 1989.
167. Lima JJ, Conti DR, Goldfarb AL, Tilstone WJ, Golden LH, Jusko WJ. Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype. J Pharmacokin Biopharm, 7, 69-85, 1979.

168. Lou Y-Ch, Ying L, Bertilsson L, Sjqvist F. Low frequency of slow debrisoquine hydroxylation in a Chinese population. Lancet, 2, 852-853, 1987.
169. Lower Jr GM, Nilsson T, Nelson CE, Wolf H, Gamsky TE, Bryan GT. N-acetyltransferase phenotype and risk in urinary bladder cancer. Approaches in molecular epidemiology. Environm Health Perspect, 29, 71-79, 1979.
170. Lunde PKM, Frislid K, Hansteen V. Disease and acetylation polymorphism. Clin Pharmacokin, 2, 182-197, 1977.
171. Macklon AF, Savage RL, Rawlins MD. Gilbert's syndrome and drug metabolism. Clin Pharmacokin, 4, 223-232, 1979.
172. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet, 2, 584-586, 1977.

173. Mahgoub A, Idle JR, Smith RL. A population and familial study of the defective salicylic hydroxylation of debrisoquine among Egyptians. Xenobiotica, 9, 51-56, 1979.
174. Mansilla-Tinoco R, Harland SJ, Ryan PJ, Berstein RM, Dollery CT, Hughes GRV, Bulpitt CJ, Morgan A, Jones JM. Br Med J, 284, 936-939, 1982.
175. March P. Metabolismo de la isoniazida. Tesis doctoral. Barcelona, 1966.
176. Marsden CD. Neurotransmitters and CNS disease. Basal ganglia disease. Lancet, 2, 1141-1147, 1982.
177. Marshall EF, Mountjoy CQ, Campbell IC, Garside RF, Leitch IM, Roth M. The influence of acetylator phenotype on the outcome of treatment with phenelzine, in a clinical trial. Br J Clin Pharmacol, 6, 247-254, 1978.